top of page

Results from an international IBD registry shows that steroids but not biologics (anti-TNFs) are associated with poor Covid 19 outcomes in IBD patients.

2.png

• Increasing age, comorbidities and steroid use were associated with adverse outcomes in IBD patients who contract Covid 19 infection.

​

• Biologic agents (like anti-TNF antagonists) does not increase the risk of hospitalization, ICU , ventilator use or death.
 

•The study concluded that maintaining IBD remission with steroid sparing regimen is warranted through out the pandemic.

​

​

Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry [published online ahead of print, 2020 May 18]. Gastroenterology. 2020;S0016-5085(20)30655-7. doi:10.1053/j.gastro.2020.05.032

bottom of page